| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Medical Oncology Department, Institut du Cancer de Montpellier, 34298 Montpellier, France. Medical Oncology Department, Hopital Robert Debre, 51092 Reims, France. Biostatistics Department, Institut du Cancer de Montpellier, 34298 Montpellier, France. Medical Oncology Department, Centre Antoine-Lacassagne, 06189 Nice, France. Medical Oncology Department, Centre Oscar Lambret, 59000 Lille, France. Medical Oncology Department, Institut de cancerologie de l'Ouest, 44805 Saint Herblain, France. Medical Oncology Department, Assistance Publique des Hopitaux de Paris, Hopital Europeen Georges Pompidou, 75015 Paris, France. Medical Oncology Department, Centre Leon Berard, 69008 Lyon, France. Digestive Oncology Department Assistance Publique des Hopitaux de Marseille, La Timone, Universite de Marseille, 13005 Marseille, France. Medical Oncology Department, Centre Alexis Vautrin, 54519 Vandoeuvre-les-Nancy, France. Medical Oncology Department, Centre Francois Baclesse, 14000 Caen, France. Medical Oncology Department, Hopital Saint Eloi, CHRU Montpellier, 34295 Montpellier, France. Translational Research Unit, Institut du Cancer de Montpellier, 34298 Montpellier, France. Pharmacology Department, Institut du Cancer de Montpellier, 34298 Montpellier, France. Pathology Department, Institut du Cancer de Montpellier, 34298 Montpellier, France. Biochemistry Department, Hopital Europeen Georges Pompidou, 75015 Paris, France. alt-title: British journal of cancer number: 5 accession-num: 24407191 |
| Tags | _EndnoteXML import |
| Date Added | 2019/05/22 - 09:42:41 |
| Date Modified | 2019/05/22 - 09:42:41 |
| Parent item | Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial |
Institut de Recherche en Cancérologie de
